
|Articles|November 1, 2004
- Volume 0 0
Children's Behavioral Medication Costs Soar
Advertisement
Medco Health Solutions 2004 DrugTrend Report has revealed eye-openingdata about medication spending totreat behavioral disorders in pediatricpatients. Specifically, spending ondrugs primarily used to treat attention-deficit/hyperactivity disorder skyrocketedby 369% for children under age 5.The number of children taking 1 ormore prescription medications to treatbehavior-related conditions hit almost9% for those children taking at least 1medication overall. Other significantfindings of the analysis are as follows:
- Prescription drug spending forbehavioral conditions rose by77% between 2000 and 2003 as aresult of increased costs and theincreased use of these medications
- In 2003, spending on behavioralmedications to treat childrenovertook both the antibiotic andasthma categories, which are traditionallyhigh-use categories inpediatric medicine
- The number of children takingbehavioral medications jumpedby >20% between 2000 and 2003,outpaced only by the increase inchildren on drugs to treat gastrointestinalconditions, whichincreased by 28%
Articles in this issue
over 21 years ago
Geriatric Pharmacologyover 21 years ago
Management of Bacterial Rhinosinusitisover 21 years ago
Early RA Treatment Proves Beneficialover 21 years ago
Topical Creams Work Temporarilyover 21 years ago
Mental Anguish Is Common with Arthritisover 21 years ago
Overview of Astrocytomas?The Pharmacist's Perspectiveover 21 years ago
Scanner Detects Hand Arthritisover 21 years ago
OA: All in the Familyover 21 years ago
Sheriff Sues Board for Searching His Rx Records Without a Warrantover 21 years ago
Restricting the Sale of Cold MedicationsAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
ADA 2026: Factors Associated With GLP-1 RA Nonresponse in T2D—and What Pharmacists Should Screen For
2
ADA 2026: Survodutide Cuts Visceral Fat and Normalizes Liver Fat in MASLD. Here's What the Data Mean for Metabolic Risk
3
ADA 2026: Optimized Inhaled Insulin Dosing Outperforms Subcutaneous Analogs for Postprandial Glucose in T1D
4
The Hidden Reimbursement Crisis in Medicare’s Drug Price Negotiation Program
5






































































































































